Revolution Medicines Inc
$ 149.23
-4.15%
05 Jun - close price
- Market Cap 31,725,769,000 USD
- Current Price $ 149.23
- High / Low $ 154.97 / 148.15
- Stock P/E N/A
- Book Value 7.49
- EPS -7.12
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.38 %
- ROE -0.77 %
- 52 Week High 166.50
- 52 Week Low 34.00
About
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Analyst Target Price
$186.33
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-02-26 | 2023-11-06 | 2023-08-08 |
| Reported EPS | -2.29 | -1.86 | -1.61 | -1.31 | -1.13 | -1.12 | -0.94 | -0.81 | -0.7 | -1.14 | -0.99 | -0.92 |
| Estimated EPS | -1.84 | -1.58 | -1.41 | -1.12 | -1.06 | -0.9645 | -0.88 | -0.76 | -0.72 | -0.88 | -1 | -0.82 |
| Surprise | -0.45 | -0.28 | -0.2 | -0.19 | -0.07 | -0.1555 | -0.06 | -0.05 | 0.02 | -0.26 | 0.01 | -0.1 |
| Surprise Percentage | -24.4565% | -17.7215% | -14.1844% | -16.9643% | -6.6038% | -16.1223% | -6.8182% | -6.5789% | 2.7778% | -29.5455% | 1% | -12.1951% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -2 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RVMD
2026-06-05 19:08:48
Revolution Medicines (RVMD) has seen its stock price soar nearly 100% this year due to impressive clinical progress with its lead drug candidate, daraxonrasib, which targets RAS-addicted cancers. While the bull case points to the drug's potential as a new standard of care with multi-billion dollar sales opportunities, the bear case highlights the significant risks associated with clinical-stage biotechs, including the company's high valuation of $33.6 billion despite generating no revenue. Investors are advised to consider waiting for a pullback due to the stock's already "baked-in" success.
2026-06-05 15:38:52
Revolution Medicines (RVMD) shares have risen 9.3% since its last earnings report, outperforming the S&P 500 despite reporting a wider-than-expected Q1 2026 loss with no revenue. The company increased its guidance for operating expenses due to higher R&D and administrative costs. While estimates for RVMD have been trending downward, an industry peer, Alkermes (ALKS), has also seen gains.
2026-06-05 09:38:52
Revolution Medicines Inc. has announced "unprecedented improvements" in overall survival rates for pancreatic cancer patients treated with their new oral drug, daraxonrasib. Clinical trials showed a 60% reduction in death risk and an increase in median overall survival to over one year, a first for Phase 3 trials in this disease. Analysts rate the stock a "Buy" with price targets up to US$263, expecting regulatory approval soon and a potential new standard of care for metastatic pancreatic cancer.
2026-06-05 08:38:52
Revolution Medicines, a clinical-stage biotechnology company, has seen its stock price surge significantly, nearly 100% in 2026 and 285% over the past year, driven by promising clinical trial results for its leading drug candidate, daraxonrasib. Daraxonrasib has shown strong efficacy in a phase 3 study for metastatic pancreatic cancer, achieving 13.2 months overall survival compared to chemotherapy's 6.7 months, sparking analyst predictions of it becoming a new standard treatment and generating billions in annual revenue. The company is also testing daraxonrasib and another candidate, zoldonrasib, for non-small cell lung cancer, targeting RAS-addicted cancers with high unmet medical needs.
2026-06-05 06:38:52
Revolution Medicines (NASDAQ: RVMD), a clinical-stage biotech company, has seen its stock price surge by nearly 100% this year due to strong phase 3 clinical trial results for its leading candidate, daraxonrasib, which targets RAS-addicted cancers. While analysts project billions in potential peak sales, the company faces significant risks as it generates no revenue and is currently unprofitable. Its high valuation of $33.6 billion, unprecedented for a clinical-stage biotech, suggests that much of its future success is already priced into the stock, making it vulnerable to any setbacks.
2026-06-05 04:10:35
Revolution Medicines, a Redwood City company, has developed an experimental drug called daraxonrasib, a pill to treat pancreatic cancer. Clinical trials showed promising results, doubling the survival rates from 6.5 months with chemotherapy to over 13 months with the new pill. Due to these promising outcomes, the FDA is fast-tracking the drug's approval process.
